Needham Downgrades Avidity Biosciences to Hold, Maintains Price Target to $65
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Needham analyst Joseph Stringer downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and maintains the price target from $65 to $65.
Needham analyst Joseph Stringer downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and maintains the price target from $65 to $65.